Harmonizome 3.0

anaplastic lymphoma receptor tyrosine kinase

This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011]

ALK and LTK ligand 1

Enables protein tyrosine kinase activator activity and signaling receptor binding activity. Involved in cell surface receptor protein tyrosine kinase signaling pathway; positive regulation of MAPK cascade; and positive regulation of neuron projection development. Is active in extracellular space. [provided by Alliance of Genome Resources, Mar 2025]

ALK and LTK ligand 2

Enables protein tyrosine kinase activator activity and signaling receptor binding activity. Involved in cell surface receptor protein tyrosine kinase signaling pathway; positive regulation of MAPK cascade; and positive regulation of neuron projection development. Is active in extracellular space. [provided by Alliance of Genome Resources, Mar 2025]

From Reactome Pathways 2024

proteins participating in the NVP-TAE684-resistant ALK mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the ALK mutants bind TKIs pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Drug resistance of ALK mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by ALK fusions and activated point mutants pathway from the Reactome Pathways 2024 dataset.

From Biocarta Pathways

proteins participating in the alk in cardiac myocytes pathway from the Biocarta Pathways dataset.

From GeneRIF Biological Term Annotations

genes co-occuring with the biological term alk in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the ALK tyrosine kinase receptor protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Nuclear-interacting partner of ALK/Rsm1-like protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From KEA Substrates of Kinases

substrates of the kinase ALK from the curated KEA Substrates of Kinases dataset.

From Pathway Commons Protein-Protein Interactions

interacting proteins for ALK from the Pathway Commons Protein-Protein Interactions dataset.

From PhosphoSitePlus Substrates of Kinases

substrates of the kinase ALK from the curated PhosphoSitePlus Substrates of Kinases dataset.

From DisGeNET Gene-Disease Associations

genes associated with the disease Alk Positive Large B-Cell Lymphoma in GWAS and other genetic association datasets from the DisGeNET Gene-Disease Associations dataset.

From LINCS L1000 CMAP CRISPR Knockout Consensus Signatures

genes differentially expressed following the ALK gene perturbation from the LINCS L1000 CMAP CRISPR Knockout Consensus Signatures dataset.

From Kinase Library Tyrosine Kinome Atlas

substrates of the kinase ALK from the Kinase Library Tyrosine Kinome Atlas dataset.

From Reactome Pathways 2024

proteins participating in the MDK and PTN in ALK signaling pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Nuclear events stimulated by ALK signaling in cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the STAT3 nuclear events downstream of ALK signaling pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by ALK pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by ALK in cancer pathway from the Reactome Pathways 2024 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the ALK INHIBITOR ASP3026 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the ALK INHIBITOR NVL-655 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the ALK/C-MET INHIBITOR TQ-B3139 drug from theDGIdb Drug Targets 2026 dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical NVP-BKM120 from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical NVP ADW742 from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical NVP-AEW541 from the curated CTD Gene-Chemical Interactions dataset.

From Guide to Pharmacology Chemical Ligands of Receptors

receptors of the NVP-AAM077 ligand (chemical) from the curated Guide to Pharmacology Chemical Ligands of Receptors dataset.

From Guide to Pharmacology Chemical Ligands of Receptors

receptors of the NVP ACQ090 ligand (chemical) from the curated Guide to Pharmacology Chemical Ligands of Receptors dataset.

From Guide to Pharmacology Chemical Ligands of Receptors

receptors of the NVP 231 ligand (chemical) from the curated Guide to Pharmacology Chemical Ligands of Receptors dataset.

From Guide to Pharmacology Chemical Ligands of Receptors

receptors of the NVP-SAA164 ligand (chemical) from the curated Guide to Pharmacology Chemical Ligands of Receptors dataset.

From LINCS Kinativ Kinase Inhibitor Bioactivity Profiles

kinases with high inhibition of kinase activity in the NVP-BHG712_PC-3 chemical bioactivity profile from the Kinativ Kinase Inhibitor Bioactivity Profiles dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_MCF7_6.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_A375_24.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_HT29_24.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_SKM1_6.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_SW948_6.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_HCC515_24.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_RMGI_6.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_MCF7_24.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_PC3_24.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_A549_6.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_VCAP_24.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_THP1_6.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the BRD-K19796430_LDE225 (NVP-LDE225)_VCAP_6.0_h_10.0_um small molecule perturbation from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From DeepCoverMOA Drug Mechanisms of Action

proteins with high or low expression in NVP-BSK805 relative to other proteins from the DeepCoverMOA Drug Mechanisms of Action dataset.

From DeepCoverMOA Drug Mechanisms of Action

proteins with high or low expression in NVP-BHG712 relative to other proteins from the DeepCoverMOA Drug Mechanisms of Action dataset.

From DeepCoverMOA Drug Mechanisms of Action

proteins with high or low expression in NVP-BEP800 relative to other proteins from the DeepCoverMOA Drug Mechanisms of Action dataset.

From LINCS L1000 CMAP Chemical Perturbation Consensus Signatures

genes differentially expressed following the NVP-BSK805 small molecule perturbation from the LINCS L1000 CMAP Chemical Perturbation Consensus Signatures dataset.

From LINCS L1000 CMAP Chemical Perturbation Consensus Signatures

genes differentially expressed following the NVP-AUY922 small molecule perturbation from the LINCS L1000 CMAP Chemical Perturbation Consensus Signatures dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_C32 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_HepG2/C3A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_J82 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_LOX-IMVI drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SW 900 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_A498 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_RKO drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_A-172 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_H4 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SW480 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SNU-423 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_Panc 03.27 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_HT-29 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_PANC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_HCT15 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_HEC-1-A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SW 1088 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SW 1271 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SW1417 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_LoVo drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_A549 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_C-33 A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_AN3 CA drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SW48 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_HOP62 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SK-MEL-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_RPMI-7951 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_hTERT-HPNE drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_LS 180 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_COLO 205 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_BT-474 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_KATO III drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_A-427 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SNU-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_SHP-77 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_CHP-212 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_NCI-H460 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_CFPAC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_AsPC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-TAE 226 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-SAA164 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-AEW541 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-2 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP 231 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-DKY709 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-BHG712 ISOMER drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-DFF332 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-BHG712 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-AAM077 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP-CLR457 drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the NVP‐TNKS656 drug from theDGIdb Drug Targets 2026 dataset.

From GeneRIF Biological Term Annotations

genes co-occuring with the biological term mutants in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by NOTCH1 PEST Domain Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the SMAD2/3 Phosphorylation Motif Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the SMAD2/3 MH2 Domain Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Constitutive Signaling by NOTCH1 HD Domain Mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the TGFBR1 KD Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by NOTCH1 HD Domain Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the AXIN missense mutants destabilize the destruction complex pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by FGFR3 mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the APC truncation mutants have impaired AXIN binding pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the APC truncation mutants are not K63 polyubiquitinated pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the S37 mutants of beta-catenin aren't phosphorylated pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by FGFR2 amplification mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the S33 mutants of beta-catenin aren't phosphorylated pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the FBXW7 Mutants and NOTCH1 in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by FGFR1 mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by FGFR1 fusion mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the TCF7L2 mutants don't bind CTBP pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by FGFR2 mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the RNF mutants show enhanced WNT signaling and proliferation pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by FGFR4 mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the truncated APC mutants destabilize the destruction complex pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the AXIN mutants destabilize the destruction complex, activating WNT signaling pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Activated point mutants of FGFR2 pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the TGFBR2 Kinase Domain Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by FGFR mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by FGFR1 amplification mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Constitutive Signaling by NOTCH1 PEST Domain Mutants pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the TGFBR1 LBD Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the S45 mutants of beta-catenin aren't phosphorylated pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the T41 mutants of beta-catenin aren't phosphorylated pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the AMER1 mutants destabilize the destruction complex pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the SMAD4 MH2 Domain Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the TGFBR2 MSI Frameshift Mutants in Cancer pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by activated point mutants of FGFR1 pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the Signaling by activated point mutants of FGFR3 pathway from the Reactome Pathways dataset.

From Reactome Pathways 2014

proteins participating in the misspliced GSK3beta mutants stabilize beta-catenin pathway from the Reactome Pathways dataset.

From Reactome Pathways 2024

proteins participating in the APC truncation mutants are not K63 polyubiquitinated pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the APC truncation mutants have impaired AXIN binding pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the AXIN missense mutants destabilize the destruction complex pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Activated point mutants of FGFR2 pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the CTNNB1 S33 mutants aren't phosphorylated pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the CTNNB1 S37 mutants aren't phosphorylated pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the CTNNB1 S45 mutants aren't phosphorylated pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the CTNNB1 T41 mutants aren't phosphorylated pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Constitutive Signaling by NOTCH1 HD Domain Mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Constitutive Signaling by NOTCH1 PEST Domain Mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Defective translocation of RB1 mutants to the nucleus pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Drug resistance in ERBB2 KD mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Drug resistance in ERBB2 TMD/JMD mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Drug resistance of FLT3 mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Drug resistance of KIT mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Drug resistance of PDGFR mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the FBXW7 Mutants and NOTCH1 in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the FLT3 mutants bind TKIs pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the FLT3 signaling by CBL mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Hh mutants abrogate ligand secretion pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Hh mutants are degraded by ERAD pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the KIT mutants bind TKIs pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the PDGFR mutants bind TKIs pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the RAS GTPase cycle mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Resistance of ERBB2 KD mutants to AEE788 pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Resistance of ERBB2 KD mutants to afatinib pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Resistance of ERBB2 KD mutants to lapatinib pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Resistance of ERBB2 KD mutants to neratinib pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Resistance of ERBB2 KD mutants to osimertinib pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Resistance of ERBB2 KD mutants to sapitinib pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Resistance of ERBB2 KD mutants to tesevatinib pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Resistance of ERBB2 KD mutants to trastuzumab pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the SMAD2/3 MH2 Domain Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the SMAD2/3 Phosphorylation Motif Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the SMAD4 MH2 Domain Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the STAT5 activation downstream of FLT3 ITD mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by AMER1 mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by APC mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by AXIN mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by CTNNB1 phospho-site mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by ERBB2 ECD mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by ERBB2 KD Mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by ERBB2 TMD/JMD mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by FGFR1 amplification mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by FGFR2 amplification mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by FLT3 ITD and TKD mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by GSK3beta mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by LRP5 mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by MAP2K mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by MAPK mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by MRAS-complex mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by NOTCH1 HD Domain Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by NOTCH1 PEST Domain Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by PDGFRA extracellular domain mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by RAF1 mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by RAS GAP mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by RAS GTPase mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by RAS mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by RNF43 mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by TCF7L2 mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by activated point mutants of FGFR1 pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by activated point mutants of FGFR3 pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by cytosolic FGFR1 fusion mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by extracellular domain mutants of KIT pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by high-kinase activity BRAF mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by juxtamembrane domain KIT mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by kinase domain mutants of KIT pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by moderate kinase activity BRAF mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the Signaling downstream of RAS mutants pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the TGFBR1 KD Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the TGFBR1 LBD Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the TGFBR2 Kinase Domain Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.

From Reactome Pathways 2024

proteins participating in the TGFBR2 MSI Frameshift Mutants in Cancer pathway from the Reactome Pathways 2024 dataset.